Twist Bioscience Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90184D1000
USD
32.81
3.11 (10.47%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Twist Bioscience Corp. stock-summary
stock-summary
Twist Bioscience Corp.
Pharmaceuticals & Biotechnology
Twist Bioscience Corporation is a synthetic biology company. The Company is developing a disruptive deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company has a semiconductor-based synthetic DNA manufacturing process featuring 10,000-well silicon platform, which is capable of producing synthetic biology tools, such as genes, oligonucleotide pools and variant libraries. Its silicon-based DNA writing platform offers synthesis of genes on silicon. Its products include clonal perfect genes and non-clonal fragments. It offers protein scanning single variant libraries. Its design methodology, coupled with its silicon-based synthesis platform, enables synthesis of each library variant positioned exactly where user wants it to be. It offers unamplified oligo pools and cloning-ready oligo pools. Its platform offers synthesis of oligonucleotide pools for specific targeting.
Company Coordinates stock-summary
Company Details
681 GATEWAY BLVD. , SOUTH SAN FRANCISCO CA : 94080
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 77 Schemes (49.73%)

Foreign Institutions

Held by 143 Foreign Institutions (27.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Emily Leproust
Chairman of the Board, President, Chief Executive Officer
Dr. William Banyai
Senior Vice President of Research and Development, General Manager of Data Storage and Director
Mr. Robert Chess
Lead Independent Director
Mr. Nicolas Barthelemy
Independent Director
Mr. Nelson Chan
Independent Director
Mr. Keith Crandell
Independent Director
Mr. Jan Johannessen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
96 Million
(Quarterly Results - Jun 2025)
Net Profit:
20 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,584 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.49

stock-summary
Return on Equity

-17.81%

stock-summary
Price to Book

3.31